Y-mAbs Therapeutics, Inc.

Good morning and welcome to YMAP's Therapeutics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. Instructions for the -and-answer session will follow the prepared remarks. As a reminder, today's conference will be recorded. I would now like to hand the call over to YMAP's head of IR, Courtney Dugan. Please go ahead.

Thank you, Operator, and good morning, everyone. Welcome to the YMAP's First Quarter 2025 Financial Results Conference Call. We issued a press release with our results this morning before the market opened. The press release and accompanying slides are available on the IR section of our website. Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model, commercialization, and product distribution plans, expectations with respect to our business realignment, expectations with respect to clinical trial data, expectations related to current and future clinical and preclinical studies and our research and development programs and regulatory submissions, potential regulatory, marketing, and reimbursement approvals, collaborations or strategic partnerships and the potential benefits thereof, expectations related to our anticipated cash runway and cash investment and the sufficiency of our cash resources and assumptions related thereto, financial guidance and estimates for the first quarter and full year of 2025 and beyond, and other statements that are not historical facts. Because forward-looking statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such statements due to a variety of factors, including those risk factors discussed in the company's previously filed annual report on Form 10K for the year ended December 31, 2024, as supplemented by the risk factors discussed in the company's quarterly report on Form 10Q for the quarter ended March 31, 2025, to be filed with the CDC today. In addition, today's discussion will include operating expenses, excluding cost of good souls, which is a non-GAAP financial measure. A description of this non-GAAP financial measure and a reconciliation of the closest-GAAP financial measure is included in today's press release and in this live presentation available on the IR section of our website at .WIMAS.com. I would like to turn the call over to our President and CEO, Mike Rossi.

Thank you, Courtney. Good morning, everyone, and thank you for joining us. Joining me today is Doug Genelkor, our Danielza Business Unit Head and Pete Frenchu, our Chief Financial Officer. I will begin by reviewing key highlights from our business units from the first quarter and how those accomplishments align to our long-term strategy, and then discuss our upcoming radio pharmaceutical R&D event on May 28. Next, Doug will provide details on our global Daniels with Sales performance and commercial strategy. Then Pete will provide a detailed account of the first quarter financial results. We made excellent progress in the first quarter of this year following our business realignment announced in January. Just to remind everyone, the company made the decision to establish two distinct internal business units, Danielza and Radio Pharmaceuticals. The effort is expected to help maximize the potential of Danielza while at the same time accelerating the development of our novel SATA CRIP platform and high-value target programs. In the first quarter, we recorded net product revenues of $20.9 million coming in at the higher end of our guidance range we provided during the fiscal year-end 2024 earnings call in March. This represents an 8% increase from the first quarter of last year. Despite a challenging environment with multiple headwinds, I'm very proud of the team's effort and resilience to deliver this caliber of results. We continue to be prudent in our spending and our financial position remains strong with $60.3 million in cash with an anticipated runway into 2027 based on our current operations. In our Radio Pharmaceuticals business unit, we completed part A of our GD2 SATA phase 1 clinical trial, trial 1001 and follow tumors. Additionally, we successfully dosed the first patient in our CD38 SATA phase 1 clinical trial, trial 1201, in patients with relapsed or refractory non-Hodgkin lymphoma, our second clinical program evaluating our novel SATA CRIP platform, and our first in hematologic malignancies. Relapsed or refractory non-Hodgkin lymphoma presents significant challenges for patients facing limited treatment options and a more aggressive disease course. We look forward to advancing our program in the trial and will update you as it progresses. As you may have seen, this morning we announced we will hold a virtual Radio Pharmaceutical R&D event on the morning of May 28th. At that time, we will provide three key updates. First, the completed data from part A of trial 1001, our GD2 SATA trial 1 clinical trial and tumors, and next steps for the program. As a reminder, part A of trial 1001 is a dose finding study. The data we plan to share will predominantly focus on the safety profile, dosing regimen, and pharmacokinetic and dosimetry details. We anticipate the clinical data will align with our preclinical model to help understand tumor uptake, which will be critical as we move into part two of the study. Second, we will review construct optimization as we move into the next stage of both our current and future programs. Specifically, we will outline changes to be made in the new construct for GD2 SATA and provide data supporting why we believe those changes will improve tumor uptake. Third, we will provide pipeline updates including new planned target programs and anticipated timeline. In the past, we've described our systematic evaluation to identify optimal targets for our platform. We will highlight the compelling commercial opportunities for extending radiation-based therapy to those indications and how we plan to do so with a fiscally prudent strategy. We look forward to providing you with these exciting updates on our radiopharmaceutical business unit in two weeks. Now, let me hand the call over to our Danielza business unit head, Doug Genilcore, to discuss our commercial progress.

Thank you, Mike, and good morning, everyone. In January, we executed an internal business unit realignment. For our Danielza business unit, the goal of this realignment was to enhance share of voice and our position within a competitive neuroblastoma US market, increase penetration and utilization of Danielza in high-volume centers, and ultimately maximize the full value of Danielza as an important anti-GD2 therapy. We believe Danielza has the potential to penetrate the US market even further and increase position utilization in high-risk relapse refractory neuroblastoma in bone and or bone marrow. Danielza is the only approved anti-GD2 therapy in that specific indication supported by a differentiated mechanism with proven clinical results. We are closely working with investigator sponsors on their trials to advance Danielza into potential new indications to further bolster its commercial potential. Our Danielza team continues to build relationships with new key institutions that have historically not been users of YMAB's differentiated anti-GD2 therapy. We see this as a real opportunity to add additional high-volume institutions and grow Danielza's market share. We are excited to be kicking off a new Maxitimab investigator-sponsored trial being led by key members of the Children's Oncology Group, or COG. We have a lot of interest from additional COG sites to work with us on even more investigator-sponsored trials, evaluating Maxitimab and other indications and lines of treatment, and we look forward to working with these sites going forward. We believe this activity, in combination with our ongoing work with the Beat Childhood Cancer Consortium, or BCC, and the New Approaches to Neuroblastoma Treatment Consortium, or NAHTS, will further grow Danielza's utilization and expand our market reach. We look forward to sharing these updates on these new partnerships as activities progress. Let's now take a look at some commercial highlights in the first quarter of 2025. We are pleased to have achieved the upper end of our first quarter guidance with total net Danielza product revenues of $20.9 million in the first quarter of 2025, an 8% increase compared to prior year period. Ex-USA Danielza net product revenues were $7.5 million, an increase of $6.7 million compared to the prior year period, driven primarily by our Name Patient Program in Western Asia, which launched in late 2024, as well as product growth in Eastern Asia and Latin America. In the US, total net product revenues for the first quarter were $13.4 million, down 28% from prior year period. The decrease was driven by a number of factors. Coming out of the end of 2024 and into the first quarter of 2025, the company saw new patient enrollments slow largely due to competitive pressure from high enrollment of patients in clinical studies and competitive market dynamics, including continued use of available maintenance therapy. Additionally, some of our largest customers' ordering patterns contribute to the -over-year US revenue decrease. As part of our business unit realignment, we have focused our Danielza commercial operations around accelerating our advocacy development, increasing new patient starts, expansion into new high-volume commercial accounts, and highlighting financial advantages of Danielza. All three of these areas of focus have shown positive returns towards the end of the first quarter and into the second quarter of 2025. One key update since our last call that Danielza, in combination with chemotherapy, has been added to the NCCN guidelines for the treatment of relapsed or refractory neuroblastoma. With Danielza now included in the NCCN guidelines, we believe this will lead to even more support and interest in our differentiated therapy for relapsed, refractory, high-risk neuroblastoma. We believe Danielza's addition to the NCCN guidelines, coupled with new anticipated investigator-sponsored studies at some of the most influential institutions, will position Danielza back on the growth trajectory in the US. With that, I'll hand the call over to Pete for a broader financial update.

Thank you, Doug, and good morning, everyone. As you heard earlier, we recorded total Danielza net product revenues of $20.9 million in the first quarter of 2025, representing an 8% increase compared to $19.4 million total Danielza net product revenues in the first quarter of 2024. The increase was primarily due to an increase in ex-US net product revenues of $6.7 million, which was partially offset by a $5.2 million decrease in US Danielza net product revenues for the first quarter of 2025 compared to the first quarter of 2024. Ex-US net product revenues were $7.5 million and $0.8 million for the three months ended March 31, 2025, and 2024, respectively, representing an 816% increase. The increase in ex-US net product revenues was driven by the main patient program in Western Asia, which was launched in late 2024, and an increase in net product sales in Eastern Asia and Latin America. We did not have any licensing revenue for the three months ended March 31, 2025, and we recorded $0.5 million of licensing revenue in the three months ended March 31, 2024. Research and development expenses were $11.4 million and $13.3 million for the quarters ended March 31, 2025, and 2024, respectively. The $1.9 million decrease in research and development expenses was primarily attributable to a decrease of $0.7 million in clinical trials due to the timing of completion in our Phase 1 GD2 SATA trial 1001, investment in our ongoing SATA programs, and a $0.9 million decrease in personnel and stock-based compensation costs, partially offset by a $0.6 million increase in outsource manufacturing and investment in our NEXITIMEV program. Selling and general administrative expenses increased $1.7 million to $13.1 million for the quarter ended March 31, 2025, compared to $11.4 million in the same period of 2024. The $1.7 million increase in selling general and administrative expenses was primarily attributable to a $0.8 million increase in personnel and stock-based compensation costs, a $0.5 million charge related to our business realignment, and a $0.4 million increase in legal expenses recorded in the three months ended March 31, 2025. We have recorded a net loss for the quarter ended March 31, 2025 of $5.2 million for a negative $0.12 per basic and diluted chair as compared to a net loss of $6.6 million for a negative $0.15 per basic and diluted chair for the quarter ended March 31, 2024. The decrease in net loss for the quarter ended March 31, 2025 was primarily driven by an increase in net product revenues and a favorable impact from foreign currency transactions. With our business unit realignment strategy announced in January of this year, we have now organized into two internal business units, Vaneza and Radiopharmaceuticals. Our business units are focused on different products and platforms. They are managed separately as business units require and also require different research, development, marketing, and operational investments. Their segment profit and losses from operations also include certain non-cash costs. Our Danielle's business unit reflects a segment profit from operations of $8.8 million, which was a 42% segment profit margin based on total revenues of $20.9 million for the first quarter of 2025. Segment profit from operations during the first quarter of 2024 was $8.7 million or 44% segment profit margin based on total revenues of $19.9 million. Our Radiopharmaceuticals business unit reflects a segment loss or investment from operations of $6.1 million and $6 million for the first quarters of 2025 and 2024 respectively. As mentioned earlier, we ended the first quarter of 2025 with cash and cash equivalents of $60.3 million as compared to $67.2 million at year ended 2024, representing an investment of $6.9 million for the first quarter of 2025. The company continues to be capital efficient and we are currently operating below our anticipated cash investment guidance for the full year of 2025. Turning now to our full year 2025 guidance, we reiterate our anticipated full year 2025 total revenue, operating expenses, and cash investment, as well as our ability to fund operations as currently planned into 2027. In addition, we are also announcing guidance for our second quarter of 2025 total revenue, which is expected to be between the range of $17 million and $19 million. This guidance range aligns with our second quarter trends in prior years, excluding stocking orders. The company is committed to providing guidance numbers that are realistic. Finally, I want to provide some color around potential tariffs that may impact our organization. Yelda is manufactured both in the U.S. and outside the U.S. today. We conducted an analysis of our supply chain to understand the potential exposure to tariffs. At this moment, we anticipate that potential tariff increases would have a minimal impact on YMAPs. We are continuing to monitor geopolitical developments as they evolve. With a strong balance and a focused business unit strategy, we believe YMAPs is well positioned to execute our strategic mission and priorities and to support the delivery of multiple anticipated milestones in the year ahead. This concludes the financial update. And now I will turn the call back over to Mike.

Thank you, Pete.

Now let's open the line for questions. Operator?

Operator? Thank you. To ask a question, please press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. We ask that you please limit to one question and one follow-up. And the first question comes from Nicole Germina with Truist. Your line is now open.

Good morning and thanks for taking my question. So for Daniel, can you just help us better understand how to think about the US and FDUS revenue dynamics and what are the push and pulls that get us to the higher end of the range?

Thanks. Nicole, thank you very much. I'll turn that over to Doug and Doug could address the...

So outside the US, we continue to see steady growth and moderate growth with our partners. But we didn't have this quarter with some of the stock-ins that we had had previous quarters. So we continue to see success and growth outside of the US, including new starts throughout Asia and the Middle East. In the US, we continue to see price increase and slowish start to the quarter. But we have seen through the end of the first quarter, into the second quarter, and uptake in enrollment and really getting back on track from a revenue standpoint, and most specifically around new starts, which is our primary focus. Aside from that, yeah, we're seeing what we're essentially expecting both in and outside the US.

And Nicole, we continue to see the -70-30 rule with USXUS, and that continues to hold true for us.

Okay, great. And I just want a quick follow-up. On your competitor in the US, do you see any more switching dynamics there, or can you help us understand those switching dynamics and how that's going to evolve for the rest of the year and long term?

Yeah, Nicole, we continue to try to expand within our current accounts, as well as targeting large accounts that we have not penetrated yet. Doug had mentioned that we've got a clinical trial going on that will increase experience within accounts that have not used the product before. And it's giving us a tailwind on that side of going after some market share that we haven't captured before.

Great. Thank you so much.

And the next question will come from Mike Aultz with Morgan Stanley. Your line is open.

Good morning. Thanks for taking the question. Maybe just another one on Danielsa. Looks like your 2Q revenue guidance does imply a little bit of a downtrend in 2Q over 1Q. You mentioned some historical trends there. Maybe just talk a little bit more about that and how to think about progress in 2Q.

Thanks. Yeah, Mike, as we look at this, there is seasonality within the product. And we're forecasting for that. Also, as you look at US versus international, a very strong start on the XUS side in the first quarter. So as the guidance goes out, I think it's realistic for us to look at this in factor in both the seasonality as well as the international prevalence pool of patients where we have treated multiple patients in Q1 that won't be available in Q2.

Yeah, Mike, I'll add a little bit more texture to your question as well on top of what Mike said. So if you look at our US sales for last year in the second quarter, we did $15.2 million while we're kind of projecting is kind of US to be slightly up quarter on quarter, year over year. XUS second quarter 2024, we had a lot of stock-ins. I think that alludes to an earlier comment that was made. If you look at second quarter 2024, we had about almost $5 million of stock-ins in Western Europe, Latin America, and Eastern Asia. We don't anticipate those stock-ins in the second quarter of this year. So when you kind of do the math on that, that really comes back to a guidance range of $17 to $19 million. I would stress, Mike, as you can kind of see with first quarter guidance, we're trying to provide you guys with the next quarter's guidance every quarter to give you guys a really good understanding and view as to some of the effects of stock and seasonality, various other things, so that we actually can kind of land in the range that we're projecting. We feel very comfortable. And again, I think as we alluded to in the script, we're just trying to be realistic about guidance. Coming back to an earlier question, full year, we still are very convinced with regards to the $75 to $90 million overall guidance range. We still believe we're going to land in that zone. Things are looking good for the full year, I think, as we view that the US will start to rebound a bit for us based upon a lot of great work that's going on in the company around the business unit realignment, and specifically Danielza. So as you guys think about your models, just adjust them accordingly as you think about kind of the second half of the year. Hopefully that helps, Mike.

Very helpful. Thanks for the additional color.

And the next question comes from Justin Walsh with Jones Trading. Your line is open.

Hi. Thanks for taking the question. I'm wondering if you can comment on any current plans for -FIT-IMAB in osteosarcoma.

Yeah, we continue to support IAS in osteosarcoma. Also, looking at the potential of developing a better diagnostic to determine GD2 expression. GD2 is very difficult as you look at the challenges around having an IHC for that. So we've learned a lot in our 1001 trial on the SADA GD2. So with that, I think we'll be able to accelerate development with better patient selection in osteosarcoma.

Great. Thanks for taking the question. Thanks,

Justin. The next question comes from Lee Watzik with Cancer. Your line is open.

Hi. Good morning. Thanks for taking our questions. Maybe just on CD38 SADA. Looks like you were the first patient. Wondering if you can just share some of the details of the Part A in terms of the number of patients that you want to enroll and those in regimen there. And then just in terms of how should we think about the timeline to data. What would be the right benchmark here? So we think that you might need similar time as you did for GD2 or it might be a little shorter. Thanks.

Yeah, Lee, thank you very much for that. We're going to have a much deeper dive on our radiopharmaceutical platform on the 28th. But just to give you a little bit of color, we dosed the first patient. It is a smaller overall subset of patients than we were looking at for our GD2. But it is a very challenging indication in the electro-precuretory non-Hodgkin's tumor group patients. That's why it was a bit challenging in finding the right patients to dose. For us, this is a platform safety study. So with that, we're looking at ways to accelerate it. But right now the plan isn't around 12 to 15 patients. So it is less patients than we saw in the 1001 trial. Thank you. Thank you,

Lee. And our next question comes from John Newman with Canaccord. Your line is open.

Hi, guys. Thanks for taking my question. Just had kind of a financial question here. Just curious if there was any effect from a Medicaid reserve perspective this quarter. I know in the past there have been some adjustments, but not sure if there was anything in the first quarter.

Thanks. Yeah, John, I appreciate it. I'll turn that over to Pete and if he could give you some clarity on that.

Yeah, John, great question. As you know from some prior quarters, we've had some significant adjustments as we've gone quarter on quarter, especially through the course of 2024. I think what I would say to you is that we're now starting to see some stabilization in Medicaid 340B, gross to net elements. So, you know, we don't anticipate major changes as we go forward kind of in 2025. I know we had some more significant adjustments in 2024 in various quarters. But again, we're starting to see some stabilization. I think some of that, especially the 340B, is associated with a bit more of the revenue shift to outside certain institutions where they actually have patients in 340B. So, and then on the Medicaid side, again, stabilization. So, it's overall, I think the answer is, you know, 2025, we don't anticipate any major kind of adjustments at this time. So, okay, hopefully that helps.

Thank you. Yes,

thank you.

And the next question comes from Jeff Jones with Oppenheimer. Your line is open.

Good morning, guys, and thanks for taking the question. Mike, you mentioned looking at a new construct for GD2-SATA to improve tumor uptake. How does that impact the plan to move forward with the Part B of the study? You know, can you speak to timing and any other impacts? Thanks.

Jeff, I appreciate it. Good question. Again, just from a top-line perspective, what we're looking to is increase the affinity to the receptor as well as the duration that it sits on the tumor, which will improve the overall uptake. There'll be a bridging study that goes on between where we are today and Part B, just to show the safety and effectiveness of the new linker. And again, it's a proprietary linker for us. So, we'll go into this much deeper on the 28th, but what we plan to do is have that out for the second half of this year with it essentially being completed early next year.

Great, thank you.

Thank you. And the next question comes from Bill Mann with Clear Street. Your line is open.

Hey, good morning and thanks. So, looking beyond -to-quarter dynamics on Danielza, obviously there's sort of a revamped commercial effort on that. What needs to happen to return to more robust long-term growth and when might we see that

take up? Thanks. Yeah, Bill, I appreciate that. And that's the exact reason we went into the two-business unit and brought in Doug to execute that. So, I'll turn it over to Doug and he can share his plans.

Yeah, so thank you. The first thing that we have been focused on, and quite frankly, the business as a whole has been focused on for the last year to 18 months is developing advocates and further developing that advocacy to be more vocal in the market. We're starting to see that reflected with the change in the NTCN guidelines that were recently announced, as well as some of our KOL development, it starts to really move us back into a position where we are in the clinical discussion when it comes to treating these very sick patients. So, the first thing starts with advocacy. The second piece is developing stronger financial messaging around Danielza and specifically around outpatient and the benefits of outpatient treatment in this disease and then finally it's around global expansion, which we referred to earlier a few different times, but finding the markets where it is preferable and viable for Danielza through our partners and where there are growth opportunities. So, we continue to follow that playbook and again, as I said earlier, we're starting to see those results, but it really starts and ends with advocacy and again, we see that change in the NTCN guidelines as a direct reflection of how we have moved the advocacy needle in our favor.

Thanks and just to up with a radiotherapy question, obviously, initial experience in the clinic is useful, but also thinking through translatability to the rest of the radiotherapy pipeline. Given GD2 is obviously a different target, it's a different tissue than CD38 and other targets that may be announced in a couple weeks, how translatable are you learning so far on the GD2 program to the rest of the platform? Thank you.

Yeah, that's another good question, Bill, and we'll definitely get into that in a much deeper way, but the changes we're making, the advances we're making are platform-related. So, as we learn from the GD2 and CD38, you go from an N of 1 to an N of 2 and as we add additional products and looking at our preclinical versus our clinical data, the changes we make will be platform-wide. So, as we move to a proprietary linker chelator that has a higher affinity and duration on the tumor, that'll be the new platform moving forward. We started with the Naked Dota as a way to get into patients quickly in a very safe way without having two different variables. So, we've isolated the safety on the GD2 SATA and we're in the process on the CD38. Now moving into the proprietary linker and chelator, it will be the same linker-chelator combinations by isotope for all of the SATA drugs moving forward. So, we have that opportunity as we learn to apply it back to all of the future constructs. Great.

Thanks.

Thanks,

Bill. And the next question will come from David Nearingharten with Wedbush. Your line is open.

Hey, thanks. Most of my questions actually were the previous questions, but I have one more relating to the platform. I know you'll go into it more, but if you're swapping the data, changing out the linker to increase affinity and residence time, I have to ask, basically, why did you open up the CD38 NHL study? Are you going to swap that out too or kind of like walk me through the reasoning there if you're on track to change out the linker and improve the SATA targeting the residence time?

Thanks. Now, David, good question. As we looked at this, it was important to get in and establish the safety of the protein. So, that doesn't change. So, the CD38 SATA construct is the same regardless of what linker-chelator combination we're using. So, the entire purpose of both the 1001 and the 1201 is looking at the overall safety of the SATA platform. And similar to the 1001 with GD2, you want to have as few variables as possible. So, maintaining the naked DOTA on the lutecium gives you that safety information you need from the CD38 so that when the safety is established as part of the bridging study for the new chelator linker, that can then be translated back in as an amendment to start looking at that as you advance the product forward for treatment. So, again, it's about establishing the safety of the protein, about the speed of getting that information, and then making the change once you have that variable down that you're confident that there's no safety signals from the protein itself.

Okay. Thank you.

And our next question comes from Kemp D'Oliver with Brookline Capital Markets. Your line is now open.

Great. Thank you. Are you seeing stabilization in the number of cycles per patient for danielzinelle?

Kemp, that's a good question.

Doug?

The stabilization is relevant, but I think overall we see the volumes remain consistent at each individual facility. There are small changes in protocols, but in general we've seen -over-year growth in the number of vials per patient in the US. We see similar trends abroad. I think the biggest area of focus for us is less around the number of vials per patient. It's more around penetrating large accounts that are utilizing a number of anti-GG2 drugs and making sure that danielza has its rightful place in that treatment paradigm. So while we will continue to support and educate on number and how each individual patient is treated from a number of vials standpoint, our real focus is making sure that the clinically relevant information is in the hands of the decision-makers, specifically the clinicians that are treating these patients.

Great. Just to follow up on your efforts with danielza, you referenced a couple of times the investigator-initiated trial essentially in the COG network. Has that trial initiated and how many sites are involved and how many sites are you trying to get involved?

So the protocols and the setup of the studies in the hands of the investigator, we're just supporting them. But

this

particular, this next study will have multiple COG facilities involved and they are key and I would say luminary facilities amongst that group. So we're quite excited about how this study is evolving and developed. We do anticipate a very near-term start, so hopefully there will be information available to the market in the very near future about the sites and what level of involvement.

Great. Thank you so much.

Thank you, Kim.

And our next question will come from Chiara Montorani with Van LaShott Kempen. Your line is open.

Hello, Kim. Thanks for taking my question. Congratulations with the progress as well. So one question for me about danielza and the inclusion in the NCC and guidelines, but also regarding indeed the new investigator-led trial in collaboration with the COGS advocacy groups. I was wondering if you could talk a little bit more. How do you see this impacting danielza's growth? Do you think that the guidelines will have an impact on shifting the clinician choice versus competitor? And also if you could repeat again, when do you anticipate that the investigator will initiate this trial, please? Thank you.

Thank you, Chiara. I'll turn it over to Doug. He can address the NCC and guidelines as well as the timing on the ISS. As

far as the NCC and guidelines are concerned, we see this as putting us on similar footing with our competition from a recommendation standpoint. Now the decision making process still exists at the clinician level. Again, back to reiterating where our focus is around educating and providing information to clinicians making decisions on a -day-out basis. But it really removes what was a headwind for some in a certain account not being included in the guideline and does provide a potential tailwind for the team and the market as a whole to reevaluate the placement of danielza in the treatment paradigm. So while and Peter referenced earlier, we're not moving into guidance. We do anticipate some more open doors for the team to have discussions clinically and again, kind of rounding into both the clinical and the financial message not related to the guidelines, but just general around treatment with danielza. So in summary, it most likely removes a headwind and provides a potential for some tailwinds now that we are referencing the guidelines from a timing on the call trial. We've been consistent with Q2. We're not changing that timeline. We think we're a matter more like days than weeks from the start of this. So we're quite excited about the start of that. And so are the investigators, quite frankly. So a lot of positive momentum for danielza in the market with some accounts that really don't have or at least previously hadn't had significant experience with the

product. I think the other thing is opening up that to multiple sites. We expect enrollment to take place and be completed and the majority of the completed in the remainder of 2025.

Thank you very much.

Thanks, here.

And our next question comes from Alex with Bank of America. Your line is open.

Hey, guys. Thanks for taking our questions. Just a couple from us. First, I'm curious that the category to a designation was expected from your side. Maybe unpack this a bit and how this, you know, stacks up versus other approved options.

Yeah, great question. As we look at this, the two eight designation for us. I mean, that is expected. And it when you look at it, the it is the level of information. So these are rare diseases. Or ultra rare diseases with small patient populations and not the widespread dating you see with drugs that are in a much larger patient population. So the two way is expected and the same as as the competitor. So with that, it gives us reassurance that we're on the same playing field. And also, it was it's a high level of confidence from the NCC and panel as well. So it's it puts us in a very good position and on a level playing field of competition.

Okay, great. That makes sense. And maybe just one one more sort of higher level. Any comments on the new appointments at FDA or CBER? Any changes in your regulatory interactions or development approach for any of your assets? Thanks.

You know, it's all reserved comment on individuals or departments or policy. But what we find is we have very close working relationships with the FDA and we're able to get our meeting schedules, get our documents reviewed. So, you know, it's I think the entire country is in a wait and see on any changes in new administrations. However, we continue to move forward and there's a lot of great people in the FDA that we've been working with for a long period of time. We continue to have the relationship. So always a positive outlook on on people doing good work in the FDA and responding accordingly and wanting to see patients get treated. So we feel very good about where we are today. And and hopefully that that continues in the future.

Appreciate the color and thanks for the questions.

I show no further questions at this time. I would now like to turn the call back to Mike Rossi for closing remarks.

Great. Thank you everyone for joining us today and discussing our first quarter 2025 results and our continued progress. We believe why Matt is well positioned to execute and achieve strategic priorities across our Daniels and radio pharmaceutical business units in 2025 and beyond. We look forward to our radio pharmaceutical pipeline update our GD to saw to face one party data read out of May 28. Look forward to seeing everybody there and have a great day.

This concludes today's conference call. Thank you for participating. You may now disconnect.